“…To our knowledge, previous along‐tract studies on WM neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) (Sarica et al, 2017) and MS (Yeatman et al, 2018) only evaluated “classic” DTI metrics, possibly underestimating biologically specific alterations. At the same time, studies exploiting the NODDI model to detect WM anomalies in ALS (Broad et al, 2019), Parkinson's disease (Andica et al, 2018), unilateral cerebral palsy (Nemanich, Mueller, & Gillick, 2019), and stroke (Mastropietro et al, 2019) variously adopted a voxel‐wise or ROI‐based approach to compute the mean of NODDI metrics, possibly underestimating regionally specific alterations. Preliminary results in stroke patients demonstrated the superior specificity of NODDI in detecting subtle WM alterations when compared to FA (Adluru et al, 2014), while studies conducted on MS patients suggested a better detection of spinal cord lesions by means of NODDI rather than DTI‐based analysis (By, Xu, Box, Bagnato, & Smith, 2017).…”